ReviewClinical epidemiology2013
Global incidence and outcome of testicular cancer.
Review in Clinical epidemiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 96 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
96 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Assessing Health-Related Quality of Life Among Survivors of Testicular Cancer: A Systematic Review.American journal of men's healthPooled it
- Ten-year experience with testicular cancer at a tertiary care hospital in a resource-limited setting: a single centre experience in Tanzania.World journal of surgical oncology · 2014Trial
- Article
- Long-term overall survival of testicular cancer: findings from a rural population-based cancer registry, Ratnagiri district, Maharashtra state, India.Ecancermedicalscience · 2026Article
- Article
- Machine Learning Model Integrating Computed Tomography Image-Derived Radiomics and Circulating miRNAs to Predict Residual Teratoma in Metastatic Nonseminoma Testicular Cancer.JCO clinical cancer informatics · 2025Article
- Testicular tumors in men aged 60 years or older undergoing orchiectomy.Translational andrology and urology · 2025Article
- Review
- Biological and therapeutic implications of sex hormone-related gene clustering in testicular cancer.Basic and clinical andrology · 2025Article
- Testicular self-examination: The role of anticipated relief and anticipated regret.British journal of health psychology · 2025Article
- Germ cell tumours of the testis: 10-year survival data from a tertiary care centre in India.Ecancermedicalscience · 2025Article
- Examining the trend of mortality of genitourinary system cancers in Babol, North Iran (2013-2021).BMC urology · 2024Article
- Article
- Causality of genetically determined metabolites on susceptibility to prevalent urological cancers: a two-sample Mendelian randomization study and meta-analysis.Frontiers in genetics · 2024Article
- Synchronous Bilateral Testicular Tumors With Discordant Histopathology: A Rare Case in an Infertile Male.Cureus · 2023Article
- Incidence and Survival of Testicular Cancers in a Province in Northern Italy and Their Association with Second Tumors.Biology · 2023Article
- Malignant testicular tumors in children: overview on 10 years of Saudi Cancer Registry.International urology and nephrology · 2023Article
- Predicting Hearing Loss in Testicular Cancer Patients after Cisplatin-Based Chemotherapy.Cancers · 2023Article
- Differences in incidence, staging, and survival of urologic cancers in patients under 65 living in the US-Mexico border region.Current urology · 2023Article
- Article
36 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTesticular cancer is a rare tumor type accounting for 1% of malignancies in men. It is, however, the most common cancer in young men in Western populations. The incidence of testicular cancer is increasing globally, although a decline in mortality rates has been reported in Western countries. It is important to identify whether the variations in trends observed between populations are linked to genetic or environmental factors.
methodsAge-standardized incidence rates and age-standardized mortality rates for testicular cancer were obtained for men of all ages in ten countries from the Americas, Asia, Europe, and Oceania using the Cancer Incidence in Five Continents (CI5plus) and World Health Organization (WHO) mortality databases. The annual percent change was calculated using Joinpoint regression to assess temporal changes between geographical regions.
resultsTesticular cancer age-standardized incidence rates are highest in New Zealand (7.8), UK (6.3), Australia (6.1), Sweden (5.6), USA (5.2), Poland (4.9), and Spain (3.8) per 100,000 men. India, China, and Colombia had the lowest incidence (0.5, 1.3, and 2.2, respectively) per 100,000 men. The annual percent changes for overall testicular cancer incidence significantly increased in the European countries Sweden 2.4%, (2.2; 2.6); UK 2.9%, (2.2; 3.6); and Spain 5.0%, (1.7; 8.4), Australia 3.0%, (2.2; 3.7), and China 3.5%, (1.9; 5.1). India had the lowest overall testicular cancer incidence -1.7%, (-2.5; -0.8). Annual percent changes for overall testicular cancer mortality rates were decreasing in all study populations, with the greatest decline observed in Sweden -4.2%, (-4.8; -3.6) and China -4.9%, (-6.5; -3.3).
conclusionTesticular cancer is increasing in incidence in many countries; however, mortality rates remain low and most men are cured. An understanding of the risks and long-term side effects of treatment are important in managing men with this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.